Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Theriva Biologics, Inc. TOVX

Healthcare  —  Biotechnology
0.22 (0.01) (4.35%) as of 25 Sep
Market cap
$10.6M
P/E
0.2×
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Theriva Biologics, Inc. (TOVX) Business Profile

Updated before January 2025

Company Overview

Theriva Biologics, Inc. (TOVX) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for the treatment of cancer and other diseases. Originally founded as Synthetic Biologics, Inc., the company underwent a rebranding to Theriva Biologics to better reflect its focus on advancing biologic-based solutions. Headquartered in Rockville, Maryland, Theriva Biologics has positioned itself as a leader in the development of oncolytic viruses and microbiome-based therapeutics. The company is led by a team of seasoned executives, including its CEO, Dr. Steven Shallcross, who brings extensive experience in biotechnology and pharmaceutical development. The leadership team is supported by a board of directors with deep expertise in healthcare, finance, and corporate governance.

Core Business Segments

Theriva Biologics operates primarily in two core business segments:

1. Oncolytic Viruses

Theriva Biologics is at the forefront of developing oncolytic viruses, which are engineered viruses designed to selectively infect and destroy cancer cells while sparing healthy tissue. The company’s lead product candidate in this category is VCN-01, an oncolytic adenovirus that has shown promise in preclinical and clinical studies for treating solid tumors, including pancreatic cancer and head and neck cancers. VCN-01 is designed to enhance the delivery of chemotherapeutic agents and improve immune system activation against tumors.

2. Microbiome-Based Therapeutics

Theriva Biologics is also advancing microbiome-based therapies aimed at restoring gut health and addressing diseases linked to microbiome imbalances. The company’s microbiome platform focuses on developing live biotherapeutic products (LBPs) that can modulate the gut microbiota to treat conditions such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). These therapies are designed to provide a novel approach to managing chronic gastrointestinal disorders.

Business Model

Theriva Biologics employs a research-driven business model that integrates cutting-edge science with strategic partnerships to bring innovative therapies to market. The company generates revenue through licensing agreements, research collaborations, and milestone payments from its development partners. By focusing on high-value therapeutic areas such as oncology and microbiome health, Theriva Biologics aims to address unmet medical needs while creating sustainable growth opportunities. The company also invests heavily in clinical trials and regulatory approvals to ensure the safety and efficacy of its products.

Strategic Direction

Theriva Biologics has outlined a clear strategic vision for its future growth:

  • Pipeline Expansion: The company is actively exploring new indications for its existing product candidates, such as VCN-01, and is investing in the development of next-generation oncolytic viruses and microbiome-based therapies.
  • Global Partnerships: Theriva Biologics seeks to expand its network of strategic partnerships with academic institutions, research organizations, and pharmaceutical companies to accelerate the development and commercialization of its therapies.
  • Sustainability Goals: The company is committed to sustainable practices in its research and manufacturing processes, aiming to minimize its environmental footprint while maximizing patient impact.
  • New Product Categories: Theriva Biologics is exploring opportunities to diversify its product portfolio by entering adjacent therapeutic areas, such as immunotherapy and precision medicine.

Competitive Landscape

Theriva Biologics operates in a highly competitive biopharmaceutical market. Key competitors include:

  • Oncolytic Virus Developers: Companies like Oncorus, Replimune, and Sorrento Therapeutics are also developing oncolytic virus therapies, creating a competitive landscape in the oncology sector.
  • Microbiome Therapeutics: Competitors such as Seres Therapeutics and Finch Therapeutics are advancing microbiome-based therapies, making this a rapidly evolving field.
  • Large Pharmaceutical Companies: Established players like Bristol-Myers Squibb and Merck have significant resources and expertise in oncology and immunotherapy, posing indirect competition to Theriva Biologics.

Despite the competition, Theriva Biologics differentiates itself through its innovative platforms and focus on addressing unmet medical needs.

Risk Factors

Theriva Biologics faces several risks that could impact its operations and financial performance:

  • Regulatory Challenges: The biopharmaceutical industry is heavily regulated, and delays in obtaining regulatory approvals could hinder the company’s ability to bring products to market.
  • Market Dependence: The company’s reliance on a limited number of product candidates increases its exposure to market risks.
  • Supply Chain Disruptions: Global supply chain issues could affect the availability of raw materials and manufacturing processes.
  • Competitive Pressure: Intense competition from both emerging biotech firms and established pharmaceutical companies could limit market share.
  • Financial Risks: As a clinical-stage company, Theriva Biologics relies on external funding and may face challenges in securing additional capital.

Recent Developments

Theriva Biologics has made significant progress in advancing its pipeline and corporate strategy:

  • Clinical Trials: The company recently announced positive interim results from its Phase 1/2 clinical trial of VCN-01 in combination with chemotherapy for pancreatic cancer.
  • Partnerships: Theriva Biologics entered into a collaboration with a leading academic institution to explore new applications for its microbiome platform.
  • Corporate Rebranding: The transition from Synthetic Biologics to Theriva Biologics reflects the company’s renewed focus on biologic-based therapies.
  • Global Developments: The COVID-19 pandemic highlighted the importance of innovative healthcare solutions, reinforcing the value of Theriva Biologics’ research and development efforts.

Investment Considerations

Investors considering Theriva Biologics should weigh the following factors:

Strengths

  • Innovative Pipeline: The company’s focus on oncolytic viruses and microbiome-based therapies positions it at the cutting edge of biopharmaceutical innovation.
  • Experienced Leadership: A seasoned management team with a track record of success in the biotech industry.
  • Strategic Partnerships: Collaborations with leading research institutions and pharmaceutical companies enhance the company’s development capabilities.

Risks

  • Early-Stage Development: As a clinical-stage company, Theriva Biologics has no approved products and is not yet generating significant revenue.
  • Regulatory and Market Risks: Delays in clinical trials or regulatory approvals could impact the company’s growth trajectory.
  • Financial Uncertainty: Dependence on external funding may pose challenges in the current economic environment.

Conclusion

Theriva Biologics, Inc. is a promising player in the biopharmaceutical industry, with a strong focus on developing innovative therapies for cancer and microbiome-related diseases. While the company faces challenges typical of early-stage biotech firms, its robust pipeline, strategic partnerships, and experienced leadership position it for long-term success. As the company continues to advance its clinical programs and explore new therapeutic areas, it has the potential to make a significant impact on patient outcomes and create value for investors.